tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Edwards Lifesciences: Strong Financial Performance and Strategic Advancements Drive Buy Rating

Edwards Lifesciences: Strong Financial Performance and Strategic Advancements Drive Buy Rating

Edwards Lifesciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joanne Wuensch from Citi maintained a Buy rating on the stock and has a $95.00 price target.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Joanne Wuensch’s rating is based on Edwards Lifesciences’ impressive financial performance and strategic advancements. The company reported a strong second quarter in 2025, with revenues reaching $1.53 billion, surpassing expectations and demonstrating a significant year-over-year growth. The Transcatheter Aortic Valve Replacement (TAVR) segment showed robust organic growth, and the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment experienced substantial sales increases, driven by successful products like PASCAL and EVOQUE.
Additionally, the company improved its gross and operating margins, and its earnings per share exceeded consensus estimates. Looking ahead, Edwards Lifesciences’ management has raised its revenue growth and earnings guidance for the year, reflecting confidence in the company’s ongoing momentum. The anticipated clinical data releases and new product launches are expected to further bolster its market position. These factors collectively support Joanne Wuensch’s Buy rating on the stock.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $90.00 price target.

EW’s price has also changed slightly for the past six months – from $68.990 to $75.800, which is a 9.87% increase.

Disclaimer & DisclosureReport an Issue

1